IVIS Lumina III In Vivo Imaging System

Product information

Overview

The IVIS Lumina III is capable of imaging both fluorescent and bioluminescent reporters. The system is equipped with up to 26 filter sets that can be used to image reporters that emit from green to near-infrared. Superior spectral unmixing can be achieved by Lumina III’s optional high resolution short cut off filters.

Features and Benefits

Market trusted technology offering the fullest suite of leading imaging technologies, reagents and support
Exquisite sensitivity in bioluminescence
Full fluorescence tunability through the NIR spectrum
Compute Pure Spectrum spectral umixing for ultimate fluorescence sensitivity
Expandable system tailored to your workflow

Specifications

Physical Specifications

Height	104.0 cm
Width	48.0 cm

Other Specifications

Brand	IVIS
Imaging Modality	Optical Imaging

References

Lim et al (2021). Bioorthogonally surface‐edited extracellular vesicles based on metabolic glycoengineering for CD44‐mediated targeting of inflammatory diseases. J Extracellular Vesicles. https://doi.org/10.1002/jev2.12077
Lee et al (2020). NIR dye-loaded mesoporous silica nanoparticles for a multifunctional theranostic platform: Visualization of tumor and ischemic lesions, and performance of photothermal therapy. J Indus. Eng. Chem. 88:99-105. https://doi.org/10.1016/j.jiec.2020.03.027
Shim et al (2019). Carrier-free nanoparticles of cathepsin B-cleavable peptide-conjugated doxorubicin prodrug for cancer targeting therapy. Jrnl. Controlled Release. 294: 378-389. https://doi.org/10.1016/j.jconrel.2018.11.032
Lee et al (2019). Crushed Gold Shell Nanoparticles Labeled with Radioactive Iodine as a Theranostic Nanoplatform for Macrophage-Mediated Photothermal Therapy. Nano-Micro Letters. 11(36). https://doi.org/10.1007/s40820-019-0266-0
Zhang et al (2019). In vivo irreversible albumin-binding near-infrared dye conjugate as a naked-eye and fluorescence dual-mode imaging agent for lymph node tumor metastasis diagnosis. Biomaterials. 217:119279. https://doi.org/10.1016/j.biomaterials.2019.119279
Singh et al (2019). A Novel Orally Active Inverse Agonist of Estrogen-related Receptor Gamma (ERRγ), DN200434, A Booster of NIS in Anaplastic Thyroid Cancer. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-18-3007
Sonoda et al (2018). A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II. Mol Ther. 26(2): 1366-1374. https://doi.org/10.1016/j.ymthe.2018.02.032
He et al (2018). Repurposing disulfiram for cancer therapy via targeted nanotechnology through enhanced tumor mass penetration and disassembly. Acta Biomater. 28: 113-124. https://doi.org/10.1016/j.actbio.2017.12.023
Jung et al (2017). Hydrophobically modified polysaccharide-based on polysialic acid nanoparticles as carriers for anticancer drugs. Int. J Pharmaceutics. 520(1-2): 111-118. https://doi.org/10.1016/j.ijpharm.2017.01.055
Kafa et al (2016). Translocation of LRP1 targeted carbon nanotubes of different diameters across the blood–brain barrier in vitro and in vivo. Jrnl. Controlled Release. 225: 217-229. https://doi.org/10.1016/j.jconrel.2016.01.031